NIAID clarified the proposal it originally issued in June and is accepting questions about the solicitation through July 16.

NIAID plans to award between three and five contracts in fiscal year 2015 to advance promising lead therapeutics to the clinical drug stage at a total of $4 million. Drugs that have already been clinically tested do not meet the requirement of NIAID's solicitation.